The Ffa Receptor Gpr40 Links Hyperinsulinemia, Hepatic Steatosis, and Impaired Glucose Homeostasis in Mouse. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/16054069
Gpr40 Gene Expression in Human Pancreas and Insulinoma. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/16289108
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. (full - 2006) http://www.ncbi.nlm.nih.gov/pmc/arti...8/?tool=pubmed
Expression of the Gene for a Membrane-bound Fatty Acid Receptor in the Pancreas and Islet Cell Tumours in Humans: Evidence for Gpr40 Expression in Pancreatic Beta Cells and Implications for Insulin Secretion. (abst – 2006) http://www.ncbi.nlm.nih.gov/pubmed/16525841
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose dependent insulin secretion and reduce blood glucose in mice. (full – 2008) http://www.ncbi.nlm.nih.gov/pmc/arti...8/?tool=pubmed
Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. (abst – 2009) http://www.ncbi.nlm.nih.gov/pubmed/19217448
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (full – 2010) http://pharmrev.aspetjournals.org/co....full.pdf+html
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (full – 2011) http://jpet.aspetjournals.org/content/339/1/228.long
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22490067
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22374408
The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors (full – 2013) http://onlinelibrary.wiley.com/doi/1...bph.12445/full
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23848179
Fasiglifam as a new potential treatment option for patients with type 2 diabetes. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
Dietary Non-Esterified Oleic Acid Decreases the Jejunal Levels of Anorectic Nacylethanolamines (full – 2014) http://www.plosone.org/article/info%...l.pone.0100365
Optimization of GPR40 Agonists for Type 2 Diabetes. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24900872
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24576779
Physiology and therapeutics of the free fatty acid receptor GPR40. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25043059
Gpr40 Gene Expression in Human Pancreas and Insulinoma. (abst – 2005) http://www.ncbi.nlm.nih.gov/pubmed/16289108
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. (full - 2006) http://www.ncbi.nlm.nih.gov/pmc/arti...8/?tool=pubmed
Expression of the Gene for a Membrane-bound Fatty Acid Receptor in the Pancreas and Islet Cell Tumours in Humans: Evidence for Gpr40 Expression in Pancreatic Beta Cells and Implications for Insulin Secretion. (abst – 2006) http://www.ncbi.nlm.nih.gov/pubmed/16525841
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose dependent insulin secretion and reduce blood glucose in mice. (full – 2008) http://www.ncbi.nlm.nih.gov/pmc/arti...8/?tool=pubmed
Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...0/?tool=pubmed
Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. (abst – 2009) http://www.ncbi.nlm.nih.gov/pubmed/19217448
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (full – 2010) http://pharmrev.aspetjournals.org/co....full.pdf+html
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (full – 2011) http://jpet.aspetjournals.org/content/339/1/228.long
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22490067
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22374408
The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors (full – 2013) http://onlinelibrary.wiley.com/doi/1...bph.12445/full
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23848179
Fasiglifam as a new potential treatment option for patients with type 2 diabetes. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
Dietary Non-Esterified Oleic Acid Decreases the Jejunal Levels of Anorectic Nacylethanolamines (full – 2014) http://www.plosone.org/article/info%...l.pone.0100365
Optimization of GPR40 Agonists for Type 2 Diabetes. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24900872
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24576779
Physiology and therapeutics of the free fatty acid receptor GPR40. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25043059